Recently, DLK2 was described as overexpressed in lethal prostate cancers, uveal melanoma, breast cancer cell lines and in patient tissues spanning three breast cancer subtypes (Luminal A, Luminal B, and Triple Negative) [15,16,17,18]. This evidence concerns the gene DLK2 and breast carcinoma.